Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multicenter Clinical Trial
100%
Intermediate-risk Prostate Cancer
100%
Low-risk Prostate Cancer
100%
Stereotactic Body Radiation Therapy
100%
Prostate Cancer
66%
Phase I Study
66%
Prostate Cancer Patients
66%
Gastrointestinal Tract
66%
Late Toxicity
66%
Maximum Tolerated Dose
33%
Phase I Trial
33%
Radiation Therapy
33%
Quality of Life
33%
Treatment Outcome
33%
Intermediate Risk
33%
Overall Survival
33%
Prostate Carcinoma
33%
Outcome Quality
33%
Patients Included
33%
Control Rate
33%
Acute Toxicity
33%
Gleason 6
33%
Gleason Score 7
33%
Biochemical Control
33%
Freedom from Biochemical Failure
33%
Distant Metastasis Free Survival
33%
Common Toxicity Criteria for Adverse Events
33%
Medicine and Dentistry
Prostate Cancer
100%
Clinical Trial
100%
Stereotactic Body Radiation Therapy
100%
Quality of Life
20%
Urinary System
20%
Clinical Stage
20%
Overall Survival
20%
Prostate Adenocarcinoma
20%
Gleason Score
20%
Biochemical Recurrence
20%
Distant Metastasis Free Survival
20%
Median Follow Up
20%
Adverse Event
20%
Nursing and Health Professions
Prostate Cancer
100%
Stereotactic Body Radiation Therapy
100%
Clinical Trial
100%
Maximum Tolerated Dose
20%
Adverse Event
20%
Overall Survival
20%
Gleason Score
20%
Prostate Adenocarcinoma
20%
Biochemical Recurrence
20%
Quality of Life
20%
Distant Metastasis Free Survival
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Prostate Cancer
100%
Adverse Event
20%
Overall Survival
20%
Prostate Adenocarcinoma
20%
Gleason Score
20%
Distant Metastasis Free Survival
20%
Biochemical Recurrence
20%
Maximum Tolerated Dose
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Overall Survival
50%
Gleason Score
50%
Distant Metastasis Free Survival
50%
Maximum Tolerated Dose
50%